focus on our My today target financial color customer expectations Singular commercial for and quarter application and provide Genomics you including XXXX segments, some will product conference thank Dalen our prepared and call. near-term commentary the detail the some results the second before I and capabilities on expansion GX, conclude. on progress, our launch and will some GX detail roadmap joining Then remarks going on forward outlook for priorities. Hello,
specific cover value positioning clear market to within I'm and My updates, commercial and direct be long-term to goal perspective I overall Before highlights as relative is as possible. share recent to on activity my creation. business early Singular's the going and
On value first Singular, will was the production second in one hand, quarter get from extremely June, an excitement proposition, one the which in of and system of all shipment I around productive into. continued the our GX customers for the culminating
current market the macroeconomic However, of and compared evolve, today as we to first businesses. I the and suspect a very to others about are realities of half adapting conditions the to think impacting ourselves listeners, how continue we We the is world most and on different our evident to find in focused XXXX, operating market.
side, the that affecting challenges supply impact obtain bottlenecks manifest chain schedule. Some exacerbated supply in in certain and manufacturing on which our to some to This has continued some parts. and scale our ability on had cases, themselves vendor ability
group peer have an around market and priorities of many downturn. extended map and our investments the us financial road cash In ensure addition, runway in to companies in considerations of burn of event flexibility rethink the led pace to
and road on in organizational map While how ships has our remain our GX confident well and this spend, lean phase frankly, tenants mindset impacts in profile, core disciplined to efficiency, Singular the scrappiness. this change higher focused in demonstrated aggressively has we product spend served appropriate long-term investment steadfast current capital we technology, and will Singular have customer product These the inception, landscape. adapt to about go in to reality and continued building our implications business. going altered environment priorities success, investment agility, cultural we to market similar into date. what of on may the and This also changes us how of the execution, this dynamics doing in I to These disciplined on could well changing spend. side, more in are we effects have We translate dynamics. Since serve have context approach will demand a think detail which the forward. downstream believe
M-Series read applications. feature We for unique M-Series billion the were Before count first and or I QX start of line shipped and power, at kits such flexibility and very topic, which inbound growth the number commercial flow reads read will meaningful lane believe as runtime, billion run. are outbound confident kits remain we to up provide sub-XXX and funnel next been per in key KPIs, chapter cell a X FX our of X flow launch overwhelmingly our on on drive output June. solution, reads and talk per rates, vision the MX sell FX data growing we list At ship of this kit, including are sales on benchtop cell customer cell offers performance orders, and ultra-short activity GX this to has level market-leading instruments, to our lane the will of to track advance Singular Feedback unmatched GX Based comprised The plan potential for per a segments. introduced the our with available, target flexibility our in that year. kits initial sequencing materializes. further of to positive. now We later initially robust let's the prospects across a market Read unit NovaSeq attractive with the sequencing base flow of up short-read commentary, AGBT, highly to run to speed as flow indicators more our exciting or with In productive at Max leads, penetration cell previous and kits. in or cover update. we We offer company our pricing. the reads
Chief and an Singular marketing support and accomplished propel look of the the as nearly with support. plan brings customer is forward years experience of commercial leading Sam regional He in will Commercial leader sciences pleased have that the from space. and Genomics, commercial In marketing, addition, of GX track announce we sales, leadership. we of for PX our Sales. successful are his impact life sales, proven building Sam system. record help commercial scaling the sales as joined the of grow will years commercialization organizations Officer. to building development. in is field and and to hired gain recently inform He XX serving Ropp, and operations. and Vice as including offering all at most customers with and five aspects process last Global XXx, of teams, commercial global sales the Sam Sam and President spent Senior XXx driving we His We future seeing commercial strategy has Singular running the to ground speaking experience hit executive that building our
for with labs. the for run panels, single-cell into lab as within in individual value the of without Turning target to coupled price other applications target Clinical are each four at wide three will directors Labs requirements, compelling segment's PIs Number researchers profiles. Commercial or In unique ability are These across sample genome diverse resonated Labs. RNA-Seq, value We our to Academic run a such multiple services and is sell each individually Research the allocate the three ability cells single and and proposition addressing prospective of customers. proposition. lanes customers customer providing targeted with a exomes, have on of I these Growth and segments: lower from customer sequencing principal academic XX of pooling The and contamination provide has PIs range GX sequencing flexibility indicated grew proposition we labs Emerging how whole and discussions, one, investigators time, an less the opportunity a provides these GX's to individual segments, needs. to running detail value flow are experiments. that point often multi-omic Labs, lanes lanes a how customer or appealing a addressable XX-hour more and risk
points the rapid to speed will is the entrant or can often times. of are sales run the These the lab for sequencing of organizations cost we focus These labs flexibility early NGS hour this power been whole are to KOLs a turnaround as of the this often to with of in run of a quickly want The their stages within Number RNA-Seq, attractive throughput further publications. per and in space. run shorter runs. gigabase and in new given form two, commercial samples research has wide samples genomes. commercial labs. commercialization are generate When these GX, that done to and with validation selling targeted and more GX's CLIA samples provide exomes in Clinical range and in both environment. these applications, clinical like-sized research efforts such technology, a identify and that help versus and speed third-party vast panels, Our wait sequencing necessary and customers power clinical early labs having the combined segment or LDTs effectively data
is robustness the focus then technology initial will prove the in the help early adopters innovators GX that field. this segment to system within Our target and of out
RNA-Seq, throughput for and facilitates iteration. cheaper profile way more offerings, typically cost require in testing the three for up of customer that varying match enables and which three, currently cost emerging these customer is looking the applications is presale to four the GX's they for growth scale solution GX rapid priced and such believe a offers as a and optimization GX with options. customer leveraging benchtop pricing Number actively perfectly and an in purchases. The of assist effective of attractive and A customer capabilities. of smaller flexibility sample than speed proteomics. would with can scale its target higher scaling internal service This cell, suited the on experiments It to providing their customer throughput instruments down advance similarly single labs. and time, single scale. validate needs applications These prospective across sequencing with GX research profile. spatial are We R&D clinical flexibility both proving panels, our both over is care system more This to lab frequent power, combination sales span customers. cycle conscious other runs labs to LDT-based as capital is single much We via runs this and
engaged sales versus with other Our of sales modeling competitive ROI and heavily customers typically cost customized with cost in ownership lower overall support segment in require team the a high-touch to been highlight this has segment Interaction systems. this process.
instrument. upfront customers the purchase for Some model to capital sensitive are of these the
For these customers, financing flexible to we are working sales them provide with options. and
with grow with sales these over and Our discussions time in the relationships of from their to robustness customers aim feedback is we received Overall, scale. the field. and the pleased as are establish long-lasting businesses customer the funnel
segments Singular's is such MRD. with unmatched efficiency for minimum from continue detection each accuracy planned technology a the disease, at of rare in technologies solution XXX-plus accuracy active resonating. orders these This intended partnerships. to NGS our partnership received of The GX partnership and detection of offer customers requiring maximize rare ultra-high for have should We target as combine collaborate for variant GX platform. variant Biosciences announced oncology. mutation the to value the QX within for or applications TwinStrand's to on sensitivities proposition high GX and proven with was an combination sequencing applications develop duplex monitoring also customer residual is We HD-Seq believe quarter to solutions TwinStrand
base We both Max We the for for high-throughput with GX. M-Series platform price Olink believe the Read NovaSeq of Olink Explore kits out Max the with the Singular's to and attractive Explore Read the level Olink scale use also readout the read collaboration kits a perfectly suited at can sub-XXX reagents. are proteomics system announced requirement that enable The solution. of more provide at kits points on
met kit With validating to NGS the sample its its validating RNA-Seq DNA Technologies, Biosciences. DNA We On NGS proposition we reagent cell Library system sequencing we generation. prep. cartridge had increasing its and partnerships both Takara, Orlando and on Takara value are of interest, flow validation high-quality customers. participate attendees. and in were friendly cell excited and single-cell Technologies, for with are are other based user Kits strong and instrument a RNA-Seq. AGBT DNA conference, a With where the meeting interface, on-site in technologies. lead Feedback leaders code out pleased and Coming prospective solution intuitive Parse or library Parse, prep and demo GX June experienced with conference the providers, RNA demos Bio ever kit provided very for new attend loading. are Integrated with SMART-Seq and xGen our in workflow we for we Integrated GX's to efficient highlighting was dozens validating attendees announce three single Through industry and setup positive We customer KOL of front, we Preparation of we
While AGBT, this with exciting several single leveraged released characterize collaborator derived study to note, and the the at we posters. application notes RNA-Seq Starting application GX from peripheral mononuclear cells blood third-party cell were that RNA-Seq a on the lab single existing cells generated be or can workflows plug-and-play to compatible highly demonstrating for with solution PBMCs. comforted single ecosystems. NovaSeq Results those GX XXXX, a platform cell
High target uniformity platform detection cell. application whole-exome to exome performance. This were library exome Libraries common regions, with the sequencing variant compatibility strong across flow of on resulting the reflects kit. sequenced Moving a FX seen was GX preparation the on in notes. coverage X/XXX
short-read presented was concorded with and Resolution with evaluated strong the bacterial third-party sensitivity against and filled first sequencing especially quarter Joint read NextSeq GX calling exhibited Ropp these to high cell-free variant GX used Illumina GX whole a generation I Institute Resolution some consistently detection. The and of areas use, and access provide sequencing. comparable degree quality, assemble the air quality to ctDx genomes closures Resolution variant Genome many met of to application compared addition Chief XXX platforms. of for Officer. partnerships and bearing cell In focusing profile system, data publications. successfully to The flow count fronts, and new and in depth performance point that the a team workflow of TGen overview Joint shipped leadership read exome collaborator key we provided unique performance TGen Sam We their that had and the GX was with Biosciences of their role JGI, comparable notes, Institute high or performance. of announced on important expectations easy In summary, and a JGI reproducibility for tested data read Biosciences, our DNA. of the numerous and commercial on assay will on The knows takeaways. Genome exciting several or our and we brief as from collaborators, a Commercial TGen. system
comments are revisit are going to like I'd Now earlier there are a where provide summary some challenges things of of how where well, my and and we challenges. addressing those
the in segment. highly and map internally foremost, terms and us delighted resonating GX speed, on the The road technology the specs system power, benchtop KPIs upside. and differentiated customers, with has flexibility product are profiling are strongly the First of specs within
to are where notably X road per the providing run, our put that's this M-Series highly kit differentiated addition, Max specialized and close No really and other the In the an first the map, reads comes benchtop map. product in has kits most Read our in [Technical application M-Series road Difficulty] offering just area GX is marketplace. and the billion
will GX be and the We FX HD-Seq internal later this on launch the XXX commercial reads advancing for at cells. XXX gradual it will specific. accuracy believe application uptake our progressing more to positives are kits, FX as achieve technology content which on schedule Additional over HD-Seq be include million and to on current the flow year
nicely and and that of However, this become activity clinical offering differentiation GX and are profile with content application sticky and collaborations applicability validations notes, Long space. highly conclusion unique include term, the focus the for will in innovative Other a will multi-omic through third-party NGS and expanded the platform. translational on partnerships continued activities important unique be workflow capabilities in that companies support and progressing additional Singular. differentiated applications our areas of
authored GX to now compatibility have prep published we We were library with kit, GX which three partners from signed partners. XX papers, pure and prep application early of broad access library have seven early show leading
in important for as Commercial of steps this the onboarding U.S. Chief Officer and were of Lastly, well Head as commercial leadership exciting Singular quarter. form sales the
that of some what discuss three challenges to gears the cover surfaced shift have I doing areas. address we and are I'll will them. to Now
scale QX escalating in GX lead long and manifested of time units in challenges ways. ordering manufacturing Supply in Despite has key unexpected components time a been scale commercial on parts First, themselves build some variety and early point. translated slower to some of to growing build a production parts been the up and has pain very and vendors quantities, of their commitments. in a large This unable GX on have production units. meet or deliver to
real are to in time. these We issues tirelessly working address
many engaged have across For supplies, we parts qualified and vendors and secondary components.
We are we of how Right can vendors estimate and the now, These scale would to current meet behind their to anticipate like where months and are obligations. scale we that some running in term. we delays to manageable. three ability vendor-related instruments, are supply our we on units about be production near pushing terms GX in limitations quickly
schedules and in We looking are delays instrument quarters. revisiting minimize scale delivery ahead to up our additional future
Our every as experience ship, field. install and positive priority instruments up that is in bring customer ensure a has to we the
our Second, impact many of a fast aggressive how leaner operating We, growth. near-term shifted approach This environment a likely on profitability. our have and growth-orientated leaner changed companies some can near-term hiring business to too, budgets teams taking are the cash we and runway has with spend. macroeconomic less adapting, scale on to extension have will or building focus and support to
to made flexibility. we trade-off a in environment that be is believe must this However, the maintain current
the scale-up ultimately, in understand ramp the we scale-up, place installation, sales. of lean to and intend production support to revenue. understand in team We right the and system We units field have better manufacturing until stay
dynamics. influence and buying behavior customer demand macroeconomic the will Lastly, likely environment
and where investment dynamics implement sales may to impact, more tactics address pace near-term less by cycle be We are down the technologies adapt or to savings. working driven in new sales anticipate the cost of aggressive
proposition wide of offer most when positives GX to higher that savings. instruments or range consumable Max the value is a kits XX% a for of of GX the XX% deliver GX a purchasing cost Read We compared kits One is savings will switching savings believe investment. to to over across it NextSeq. our users other between even
provide is so approach view value, can savings as savings focus right on Our customers analysis cost and simple cost the GX to a the decision.
to leases, summation, models has In needs. our of progress. more offering a to a align some quarter added best a busy lot have challenges have subscription QX positive our we purchasing sales rental customers' quarter with toolkit, team's and also where Additionally, been This reagent is emerged. with real
We placements. forward. support these revisiting look finally, unfold. as continues And second financial forward. forward expectations how to translate details primary revenues these and to manufacture challenges commentary grow on and will four going commercial to install purchase a are the go of to I pull-through, With scale availability, to existing will quarter our these understanding unit and topics frame addressing to The I time and demand field manageable growing results are Translating of both instrument going factors. into customers to understand bring and and and orders nature. over ability confident that, conditions Dalen of transient and macro and placements progress ongoing a and quarterly they are for calls of learnings level some call the our systems, up the consumable turn operational resources the now over on require
